The Department of Homeland Security is asking for the Internal Revenue Service to help crack down on immigration, according ...

Read the full newsletter here, and subscribe to his newsletter here. We’re roughly two months away from Opening Day, but the offseason is in the books as regards one key metric: All new Minor League ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be implemented over the next 18 months. Published first ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

In advance of a milestone season at Whataburger Field, the Corpus Christi Hooks are making a change. The Houston Astros' Double-A affiliate unveiled new logos and uniforms on Friday evening, marking ...

I’m yet to invest in the stock as I already hold shares in Reckitt and GSK. However, I think it’s a good long-term investment to consider and one I’ll be keeping an eye on this year.

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

In a famously cyclical sector, I’d be daft to sell when the shares are down. Long-term GSK investors can be forgiven for feeling grumpy. The stock’s down 18% on a decade ago. And although ...